close
close

Bristol-Myers Squibb Likely to Get Higher Valuation After New Drug Approval (NYSE:BMY)

This article was written by

Zvi offers advisory services for companies, foundations and private individuals, including advice on retirement planning and estate planning. Zvi is licensed to practice law in New York State and provides cash management, Bitcoin and trust protector services there. Zvi is also The Claw of The Lava Empire and an Amazon influencer. The articles or discussions listed here do not represent any legal, fiduciary or advisory role, but are intended solely as informative press and/or a starting point from which, ideally, further constructive discussions can follow. Comments are welcome, as are questions.

Analyst Disclosure: I/we have an advantageous long position in the shares of BMY, MRK, either through equity ownership, options or other derivatives. I wrote this article myself and it expresses my own opinion. I receive no compensation for this (except from Seeking Alpha). I have no business relationship with any company whose shares are mentioned in this article.

I'm looking for Alpha's disclosure: Past performance is no guarantee of future results. No recommendation or advice is given as to whether an investment is suitable for a particular investor. The views or opinions expressed above may not reflect those of Seeking Alpha as a whole. Seeking Alpha is not a licensed securities dealer, broker, or U.S. investment advisor or investment bank. Our analysts are third-party authors, including both professional investors and individual investors, who may not be licensed or certified by any institution or regulator.

You may also like...